Summary Fifteen post-menopausal patients with advanced breast cancer were treated with the LH-RH agonist leuprorelin (D-leu6-des-gly'0-Gn-RH-ethylamide) given in a dosage of 7.5 mg as a monthly subcutaneous depot injection, to assess the clinical activity and endocrine response (Stoll, 1979). More surprisingly, these agents have also been reputed to be effective in 16-20% of post-menopausal patients with advanced breast cancer (Harvey et al., 1981; Plowman et al., 1986) . It has been suggested that response in this group may be due to a direct effect on the tumour, as some LH-RH agonists have been shown to have an inhibitory effect on breast cancer cells in vitro (Blankenstein et al., 1985; Miller et al., 1985) , and LH-RH binding sites have been demonstrated in several breast cancer cell lines (Eidne et al., 1987) .
Summary Fifteen post-menopausal patients with advanced breast cancer were treated with the LH-RH agonist leuprorelin (D-leu6-des-gly'0-Gn-RH-ethylamide) given in a dosage of 7.5 mg as a monthly subcutaneous depot injection, to assess the clinical activity and endocrine response to treatment. None of the 15 patients showed an objective response to treatment, although four patients had stable disease for at least 6 months. No toxicity was demonstrated. Endocrine effects after 4 weeks' treatment were as follows: mean levels of serum gonadotrophins fell to 10% of their pretreatment values; there were no significant changes in the levels of prolactin on treatment; there was a significant decrease in the levels of serum testosterone in 12 out of 14 patients; there were no significant changes in the levels of oestradiol, androstenedione and oestrone. The lowering of serum testosterone suggests that androgens in post-menopausal women may be partly produced by the ovaries, stimulated by LH and FSH. This fall in testosterone may explain why some post-menopausal breast cancer patients in other studies have been reported to respond to treatment with LH-RH agonists, as it would decrease the substrate for the peripheral synthesis of oestrogens.
Luteinising hormone-releasing hormone (LH-RH) agonists cause a reduction in the levels of plasma oestrogens in premenopausal women when given in a continuous, nonpulsatile manner. This is a result of down-regulation of pituitary receptors, which causes a decrease in the release of luteinising hormone, leading to a reduction in ovarian oestrogen synthesis (Furr & Milstead, 1988) . Several of these agonists have been used in the treatment of premenopausal patients with metastatic cancer, with response rates of 30-40% (Klijn et al., 1982; Harvey et al., 1983; Nicholson et al., 1985) , similar to the results with oophorectomy or radiation-induced menopause (Stoll, 1979) . More surprisingly, these agents have also been reputed to be effective in 16-20% of post-menopausal patients with advanced breast cancer (Harvey et al., 1981; Plowman et al., 1986) . It has been suggested that response in this group may be due to a direct effect on the tumour, as some LH-RH agonists have been shown to have an inhibitory effect on breast cancer cells in vitro (Blankenstein et al., 1985; Miller et al., 1985) , and LH-RH binding sites have been demonstrated in several breast cancer cell lines (Eidne et al., 1987) .
More recently, it has been shown that in post-menopausal breast cancer patients treated with an LH-RH agonist (goserelin), there was a significant reduction of serum testosterone levels, which was associated with a 22% fall in the level of serum oestradiol (Dowsett et al., 1988) . It is therefore possible that the response of post-menopausal patients to treatment with LH-RH analogues may be due to decreased oestrogenic stimulation, rather than to a direct, inhibitory effect on the tumour.
In this study, the clinical and endocrine response of 15 post-menopausal patients with advanced breast cancer was evaluated during their treatment with the LH-RH agonist leuprorelin (D-leu6-des-gly'0-Gn-RH-ethylamide) ( Table I . After an initial assessment, which included physical examination, chest X-ray, isotope bone scan, liver ultrasound, electrocardiogram and urinalysis, treatment was commenced with 7.5 mg of leuprorelin given subcutaneously every fourth week. The leuprorelin was given as a depot injection, through a small gauge needle (23G), the drug being formulated as polylactic/polyglycolic acid microspheres. Blood samples for full blood count, platelets, urea and electrolytes, calcium, phosphate, liver function, and levels of gonadotrophins, oestrone, oestradiol, androstenedione and testosterone were taken pre-treatment, at weeks 1, 2 and 4, and thereafter just before each subsequent injection. Chest X-ray, bone and liver scans were repeated at 3-monthly intervals, and at suspected relapse. Treatment was discontinued when there was objective evidence of disease progression according to the WHO criteria of response (World Health Organization, 1979) .
Five women had received no previous hormone therapy and 10 had previous treatment with tamoxifen, which in all cases had been stopped at least 4 weeks before commencing the leuprorelin therapy. No patients had received any other endocrine therapy. Two women had also previously received chemotherapy (melphalan and 5-fluoro-uracil, and methotrexate, mitoxantrone and mitomycin C). Of the women who had received therapy with tamoxifen, the mean length of time to progression was 17.7 ± 14.1 ( ± s.d.) months, with a range of 6-54 months. Three out of the 10 patients had shown an initial partial response to tamoxifen but had subsequently relapsed on treatment.
Hormone measurements Serum samples were stored at -20C and assayed in batches for luteinising hormone (LH), follicle stimulating hormone (FSH), prolactin (Prl), oestradiol (E2), oestrone (El) , androstenedione (M'A) and testosterone (T) by radioimmunoassay techniques which have been described previously (Ferguson et al., 1982; Dowsett et al., 1983 Dowsett et al., , 1984 Dowsett et al., , 1987a Harris et al., 1982 Harris et al., , 1983 . All samples from the same patient were analysed in the same batch. The intra-and inter-assay coefficients of variation were < 10% and < 15% respectively for all analytes. Figure 2 as a percentage of the pretreatment value (geometric means and 95% confidence intervals). The arithmetic mean serum hormone levels before and after 4 weeks' treatment are shown in Table III . The most marked changes are seen in the levels of LH and FSH. LH levels fell to 63.4% of the pretreatment level at week 1, 28.5% at week 2 and 8.7% at week 4. Thereafter, they ranged between 6.2% and 10.2% of pretreatment levels. FSH fell more rapidly, to 30% of the pretreatment level at week 1, 10.3% at week 2 and 4.9% at week 4. Thereafter they varied between 5.8% and 14.5% of the pretreatment level. Five patients had pretreatment FSH levels which were less than 20 IU 1'. However, all five patients were aged over 60 years, and these low levels probably reflect the decreased gonadotrophin secretion associated with advanced menopause.
Serum Prl levels showed no significant changes, although three individual patients showed marked increases in Prl levels to above 500 mIU 1`at the time of their disease progression.
Mean serum T levels fell significantly during treatment, to 74.1% of pretreatment levels at 4 weeks. Thereafter, the levels remained lower than the pretreatment levels at all time points. After 4 weeks' therapy, 12 out of the 14 patients on whom we had paired samples showed a lowering of their testerone levels (Figure 3) , this being most marked in the patients whose pretreatment levels were greater than 1.5 nmol-'. In these seven patients, levels fell from 2.09 ± 0.46 nmol 1' (mean ± s.d.) to 1.30 ± 0.43 nmol [1-'. In the seven patients with baseline levels less than 1.5 nmol 1-', the levels fell from 1.25 ± 0.17 nmol 1' to 1.16 ± 0.27 nmol 1-'. In two patients, the serum testosterone levels showed a slight rise at 4 weeks. Mean M4A levels were also lower than the pretreatment levels for the first 4 weeks of therapy, but thereafter ranged between 87.3% and 132% of pretreatment levels. E2 levels fell to 85.6% of the pretreatment value at week 4, and thereafter varied between 82.9% and 116% of pretreatment levels. In nine out of 14 patients, E2 levels fell after 4 weeks' therapy, in three patients levels increased and in two patients they remained unchanged (Figure 3 ). These changes were not as marked as the changes in the testosterone levels; statistical significance was approached only after 4 weeks. One patient had a pretreatment and on treatment level of > 100 pmol 1'. This patient was the heaviest patient in the study (108.5 kg), and also had the highest level of El. Mean El levels fell to 85.0% of the pretreatment levels at 4 weeks, and thereafter ranged between 76.3% and 102.1% of the pretreatment levels. Table 111 . (n = 9) 116.2%
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The percentages were compared to 100% using paired t tests, after performing a logarithmic transformation.
biologically of interest to perform a larger study to define more precisely the response rate to these agents in postmenopausal patients this would be difficult to justify in circumstances where there are other clearly more effective agents from which to choose.
Endocrine measurements have confirmed that leuproreliin is a potent suppressor of LH and FSH levels, with a >90% fall in serum levels after 4 weeks, which was maintained for as long as therapy was continued. We have also demonstrated that leuprorelin causes a significant lowering of serum testosterone levels, particularly in those patients with pretreatment levels of greater than 1.5 nmol 1-'. This confirms the findings of Dowsett et al. (1988) in goserelin-treated patients, and would support the suggestion that androgens in post-menopausal women may partly be produced by the ovaries, under the stimulation of pituitary gonadotrophins. There was a 15% drop in serum E2 levels after four weeks treatment, but this was of only borderline statistical significance (0.05 < P <0.10), and was not sustained consistently, nor was any lowering of E2 levels associated with any lengthening of the time to progression of the disease. Although there are differences between the current study and that on goserelin treatment in the magnitude and statistical significance of the changes in plasma steroid hormone levels, the two studies are largely consistent in their indication of an ovarian suppressant effect of LHRH agonists in post-menopausal women which results in a relatively modest suppression of circulating androgen and oestrogen levels. These differences between the studies probably reflect the withinpatient variability of the four steroids (Lonning et al., 1989) and the between-patient variability in the endocrine response to LHRH agonist treatment.
One other interesting endocrine observation was that in three patients, serum prolactin levels rose markedly at the time of progression (from levels of 100, 110 and 130 mlU 1-', to 1300, 560 and 670 mlU I-', respectively). This has previously been noted in patients progressing on other hormonal and cytotoxic treatments (Holtkamp et al., 1984; Dowsett et al., 1987b) . It is probable that this is a result of, rather than a cause of, the disease progression.
In conclusion, leuprorelin in our hands was largely ineffective as a single agent therapy for the treatment of post-menopausal breast cancer. However, in 12 out of 14 patients, there was a decrease in the levels of serum testosterone, and, since androgens are a substrate for the peripheral production of oestrogens (Grodin et al., 1973) , it may be that combination endocrine therapy with an LH-RH agonist (to decrease the substrate for peripheral oestrogen synthesis), and an aromatase inhibitor (to suppress conversion of the substrate) would be more effective than treatment with an aromatase inhibitor alone.
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